174 related articles for article (PubMed ID: 29449411)
21. Molecular Imaging in Drug Discovery and Development.
Lindner JR; Link J
Circ Cardiovasc Imaging; 2018 Feb; 11(2):e005355. PubMed ID: 29449411
[TBL] [Abstract][Full Text] [Related]
22. Applications of molecular imaging in drug discovery and development process.
Ahn BC
Curr Pharm Biotechnol; 2011 Apr; 12(4):459-68. PubMed ID: 21342108
[TBL] [Abstract][Full Text] [Related]
23. Application of molecular imaging technologies in antitumor drug development and therapy.
Lin Y; Chen ZY; Yang F; Zhang JS; Wang YX; Liu JB; Liao JY; Liao YY; Zhou QL; Li BC; Liang HY
Curr Pharm Des; 2015; 21(16):2136-46. PubMed ID: 25578891
[TBL] [Abstract][Full Text] [Related]
24. Toward molecular imaging-driven drug development in oncology.
de Vries EG; Oude Munnink TH; van Vugt MA; Nagengast WB
Cancer Discov; 2011 Jun; 1(1):25-8. PubMed ID: 22586317
[TBL] [Abstract][Full Text] [Related]
25. [Molecular imaging-based early-phase and exploratory clinical research].
Watanabe Y
Yakugaku Zasshi; 2013; 133(2):187-95. PubMed ID: 23370512
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography molecular imaging for drug development.
Matthews PM; Rabiner EA; Passchier J; Gunn RN
Br J Clin Pharmacol; 2012 Feb; 73(2):175-86. PubMed ID: 21838787
[TBL] [Abstract][Full Text] [Related]
27. FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines.
Liberti L; Bujar M; Breckenridge A; Hoekman J; McAuslane N; Stolk P; Leufkens H
Front Pharmacol; 2017; 8():161. PubMed ID: 28420989
[TBL] [Abstract][Full Text] [Related]
28. Introducing Therioepistemology: the study of how knowledge is gained from animal research.
Garner JP; Gaskill BN; Weber EM; Ahloy-Dallaire J; Pritchett-Corning KR
Lab Anim (NY); 2017 Mar; 46(4):103-113. PubMed ID: 28328885
[TBL] [Abstract][Full Text] [Related]
29. 2016 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2017 Feb; 16(2):73-76. PubMed ID: 28148938
[No Abstract] [Full Text] [Related]
30. Trends In Orphan New Molecular Entities, 1983-2014: Half Were First In Class, And Rare Cancers Were The Most Frequent Target.
Miller KL; Lanthier M
Health Aff (Millwood); 2016 Mar; 35(3):464-70. PubMed ID: 26953301
[TBL] [Abstract][Full Text] [Related]
31. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
[TBL] [Abstract][Full Text] [Related]
32. Why the drug development pipeline is not delivering better medicines.
Naci H; Carter AW; Mossialos E
BMJ; 2015 Oct; 351():h5542. PubMed ID: 26496934
[No Abstract] [Full Text] [Related]
33. Imaging inflammation and neovascularization in atherosclerosis: clinical and translational molecular and structural imaging targets.
Osborn EA; Jaffer FA
Curr Opin Cardiol; 2015 Nov; 30(6):671-80. PubMed ID: 26398413
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and Features.
Stendahl JC; Sinusas AJ
J Nucl Med; 2015 Oct; 56(10):1469-75. PubMed ID: 26272808
[TBL] [Abstract][Full Text] [Related]
35. Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk.
Jørstad HT; Colkesen EB; Boekholdt SM; Tijssen JG; Wareham NJ; Khaw KT; Peters RJ
Heart; 2016 Jan; 102(1):63-8. PubMed ID: 26261158
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
